Definitive Contract 75A50120C00160

Award Date 8/10/20
Potential Completion Date 6/30/21
Potential Value $749K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
East Watertown, MA 02472, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
500
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a Cost Plus Fixed Fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Vaxxas PTY LTD, a for-profit company based in Australia, for the development of a Micro Array Patch (MAP) to deliver a vaccine against the H5N1 pandemic strain of influenza. The total ceiling value of the contract is $28,521,971.80 with a period of performance through December 30, 2026. No set-aside designation was used for this award. The University of Queensland, also...
This $100,000,000.00 definitive, firm fixed-price contract was awarded by the Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services. The contract is for the design and administration of incentive prize competitions to accelerate the development and commercialization of new medical countermeasure technologies, with an initial focus on...
The Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response awarded a $29.9 million delivery order to Protein Sciences Corporation under the Pandemic Influenza Preparedness and Response 2016-2021 master IDIQ contract. The delivery order is for non-clinical and Phase I clinical studies of a stabilized pre-fusion trimer of the spike protein COVID-19 vaccine candidate reconstituted with two adjuvants, AS03 and AF03, to be performed in Meriden,...
This is a federal contract award to Protein Sciences Corp, a for-profit vaccine manufacturer, by the U.S. Department of Health and Human Services' (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR). The $2,146,389.00 firm fixed-price contract is a delivery order under ASPR's Pandemic Influenza Preparedness and Response 2016-2021 master IDIQ contract. The purpose of the award is for Protein Sciences to manufacture 1 bulk lot of an H7 vaccine. No set-aside designation was...
The federal agency Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $338,869,093.00 Firm Fixed Price definitive contract to Castlevax Inc. to develop a next-generation, mucosally delivered, COVID-19 booster vaccine capable of eliciting mucosal immunity and protecting against SARS-CoV-2 breakthrough infection and transmission. The contract has an ultimate completion date of August 2, 2027. The contract opportunity originated from a Broad Agency Announcement (BAA)...
This is a $432,990 firm fixed price contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response to the University of Connecticut to develop a single-administration microneedle skin patch for novel vaccination technology. The contract supports the national interest in response to the coronavirus pandemic. The University of Connecticut is a public research institution that frequently conducts work for the federal government...
This definitive contract was awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to Moderna US, Inc. for COVID-19 vaccinations in support of the 2022 Fall Vaccine Campaign. The $7.8 billion firm fixed price contract is a transfer from the original awarding agency, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, and represents continuation of vaccine production...
This federal contract award, valued at $7,521,000.00, was issued by the Centers for Disease Control and Prevention (CDC) to Protein Sciences Corp, a for-profit manufacturer, to conduct research, development, manufacturing, and testing of vaccine candidates, antigens, proteins, seed lots, and assays to support medical countermeasure preparedness against influenza strains and COVID-19. The award is part of the Department of Health and Human Services' (HHS) Office of the Assistant Secretary for...
This federal contract award was issued by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Protein Sciences Corp, a for-profit manufacturer, under ASPR's Pandemic Influenza Preparedness and Response 2016-2021 master Indefinite Delivery/Indefinite Quantity (IDIQ) contract. The $357,198.29 Firm Fixed Price delivery order supports Protein Sciences' research, development, manufacturing, and testing of vaccine candidates, antigens,...
The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded a firm-fixed-price purchase order contract worth $248,887.50 to Boston Bioscience Inc., a for-profit organization, for the synthesis of COVID-19 related proteins. The contract was awarded on a sole-source basis, without a set-aside, to support the Vaccine Research Center's efforts in analyzing immune responses to SARS-CoV-2 infection and vaccination. The...

This definitive contract award of $749,000 by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response is for Vaxess Technologies Inc. to deliver its MIMIX-COVID pre-fusion spike protein vaccine patch at scale. The prime contractor will manufacture up to 100 million shelf-stable, self-applied single-dose vaccine patches in response to Special Instructions 019 under the Easy Broad Agency Announcement BAA-20-100-SOL-0002. This solicitation sought host-directed therapeutic candidates to aid long-term outcomes from lung injury. The contract period is from August 10, 2020 through June 30, 2021. No subcontractors or set aside designations were indicated. The award provides funding to advance the company's COVID-19 vaccine patch through safety review and Phase I clinical trials, in support of the agency's pandemic response efforts.

Generated 12/29/23, 4:08 PM